GPT and metabolic dysfunction-associated steatotic liver disease: Compared with the control group, hepatic TGs (0.1796±0.0357 μmol/mg prot vs 0.0811±0.0158 μmol/mg prot, P<0.01), and serum AST (398.20±104.5549 U/l vs 209.80±33.4226 U/L, P<0.01), ALT (123.50±28.5161 U/L vs 50.50±7.5019 U/L, P<0.01),TGs (4.307±0.6459 mmol/l vs 1.9370±0.2393 mmol/l, P<0.01),TC (0.649±0.1384 mmol/l vs 0.428±0.0803 mmol/l, P<0.01) in the NAFLD group increased significantly (Figure 1A, 1B, and 1C).